Is there a limited scope of Artificial Intelligence in Healthcare?

Team Veye | 30-Sep-2019 Artificial Intelligence in Healthcare

Last week we had concluded that Artificial Intelligence emphasizes the development of intelligent machines that think and work like humans. And that ultimately everything would be done by machines and humans controlling them.

Recent AI techniques have fuelled active brain storming sessions on which all fields will derive maximum advantage from it. And first and foremost field that can derive best benefit seems to be healthcare. Over the years, medical technology has become increasingly reliant on vast healthcare data and the progress in its analysis.

AI in healthcare has huge potential. Artificial Intelligence can help physicians in making much better clinical decisions. Applications of Artificial Intelligence in healthcare are endless. Major disease areas that use AI tools include cancer, neurology and cardiology.

Artificial intelligence in healthcare refers to the use of complex algorithms designed to perform certain tasks in an automated fashion. When researchers, doctors and scientists feed data into computers, the newly built algorithms can review, interpret and even suggest solutions to complex medical problems.

Another strong application is the use of AI in interpreting medical images – a field that relies on deep learning, a sophisticated form of machine learning in which a series of labeled images are fed into algorithms that pick out features within them and learn how to classify similar images.

There are many health and pharma companies in Australia which are currently using Artificial Intelligence to help with drug discovery and improve the lengthy timelines and processes. The use of Artificial Intelligence is not limited to these only. It is being explored in pain management and improving patient outcomes also.


Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website, and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.

veye logo

Grab Your Free Report On 5 ASX Dividend Stocks To Buy In 2024